NCT06195111Not yet recruiting
A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With mCRC (REFLECT Study)
A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With Metastatic Colorectal Cancer (REFLECT Study)
Source: ClinicalTrials.gov · Last updated 8 Jan 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
A real-world study of trifluridine/tipiracil containing regimen for the treatment of patients with metastatic colorectal cancer. A total of 200 patients planned to be enrolled.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 24 Dec 2023
- Start date
- 1 Mar 2024
- Primary completion date
- 1 Mar 2027
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Diseases
- Colorectal cancer
- NCT number
- NCT06195111
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Mar 2024 to the primary completion date, 1 Mar 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Failure to sign informed consent;
- Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation.
Other
- Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study:
- Patients with contraindications to Trifluridine/Tipiracil;
- Female subjects who have a positive pregnancy test or are breastfeeding;
Who the study is looking for
- Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:
- Male and female patients with ≥18 years of age;
- Patients with metastatic colorectal cancer confirmed by histopathology;
- Be willing to use reliable contraceptive methods and refrain from sperm donation throughout the study period and within 3 months after the last dose;
- Voluntarily join the study and provide written informed consent to participate in the study;
- Have traceable medical history during the treatment;
- Doctor believe the patients can benefit from the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.